Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$1.01
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.01
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$0.31 - $2.75
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$3.25M
Enterprise Value-$4.00T
Total Cash (Recent Filing)$4.31T
Total Debt (Recent Filing)$306.71B
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.22
Shares Outstanding9,277,819
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.46
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.23M
Enterprise Value/Revenue-790.20K
Enterprise Value/Gross Profit2.36M
Enterprise Value/Ebitda854.34K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Abuse-deterrent Technologies (TAAP, MPAR)Ensysce's TAAP and MPAR platforms represent durable product differentiation in opioid analgesics. Proprietary abuse-deterrent and overdose-protection technology can create intellectual property barriers, support regulatory interest and licensing/partnering opportunities, and sustain strategic value if clinical progress continues.
Committed Financing Line And Recent $2M Private CloseThe $2M close plus a committed tranche up to $20M over 24 months materially extends near-term runway, enabling continued development of TAAP/MPAR programs without an immediate public equity raise. This committed funding provides durable operational flexibility to advance clinical milestones.
Improved Balance Sheet: Low Leverage, Positive Equity In 2025Moving to positive equity and a low debt-to-equity ratio improves solvency and financial flexibility versus prior years of negative equity. This healthier capital structure makes it easier to negotiate partnerships or debt financing and reduces immediate bankruptcy risk while R&D progresses.
Bears Say
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating and free cash flow increases financing dependency and shortens runway absent material non-dilutive funding. Ongoing cash burn elevates execution risk for clinical programs, forces repeated capital raises, and can materially constrain long-term strategy if capital markets tighten.
No Established Commercial Revenue; Clinical-stage StatusAs a clinical-stage biotech with effectively no product revenue, Ensysce lacks a self-sustaining cash generation model. Long-term viability depends on successful clinical outcomes or non-dilutive partnerships; absent commercialization, persistent losses and financing needs are structural risks to shareholder value.
Convertible Preferred And Warrants Create Dilution RiskThe recent financing's convertible preferred stock and large warrant pool create a material overhang and potential dilution for common holders. Anti-dilution provisions and conversion mechanics complicate the capital structure, can deter new financing on favorable terms, and may reduce future economic upside for existing shareholders.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.31 and its highest was $2.75 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $3.25M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is May 18, 2026 which is in 8 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Mar 30, 2026. The company reported -$0.75 earnings per share for the quarter, beating the consensus estimate of -$1.26 by $0.51.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 9,277,819 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.75 in its last earnings report, beating expectations of -$1.26. Following the earnings report the stock price went up 4.669%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Technical Analysis
Ownership Overview
―
Insiders
0.36% Mutual Funds
0.17% Other Institutional Investors
99.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---